If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Rilwanu Lukman- former Minister of Petroleum Resources and Mines, Power, Steel; and former secretary general OPEC. Maikanti Baru - engineer, former GMD Of NNPC Limited. Mohammed Bello-Koko - former managing director of the Nigerian Ports Authority Muhammed Babandede - former Comptroller General (CG) of the Nigeria Immigration Service NIS. Ahmad Salihijo Ahmad - former managing director of Nigerian Rural Electrification Agency. M.T. Usman - former permanent secretary ministry of Works. Abubakar Dantsoho - Managing Director of the Nigerian Ports Authority (NPA). Hamman Bello - former Comptroller- General Of Nigeria Customs Service. Musa Yar'Adua - Minister of Lagos Affairs 1960 -1966, Matawalle of the Katsina Emirate. Muhammadu Ribadu – first minister of defence after independence, founder of the Nigerian Defence Academy. Mansur Muhtar – economist, former Nigerian Federal minister of finance (2008 -2010), former director World Bank, presently vice chairman, Islamic Development Bank. Tajudeen Abbas - Speaker of the House of Representatives of Nigeria. Abubakar Olusola Saraki – (Fulani/Yoruba); former president of the Senate. Gbemisola Ruqayyah Saraki – (Fulani/Yoruba); former Senator Kwara Central, current Minister of State. Transportation of the Federal Republic of Nigeria. Nigeria. Aisha Dikko - former attorney general, commissioner of Justice Kaduna. Bukola Saraki – (Fulani/Yoruba); former president of the Nigerian Senate; former Governor of Kwara State and former Senator Kwara Central, Nigeria. Captain Muhammad Bala Shagari – politician, former Nigerian Army officer.
== References == Nordin G, Dybkaer R. Recommendation for term and measurement unit for "HbA1c". Clin Chem Lab Med 2007; 45(8):1081-2. Summary of NPU definition publications René Dybkær: "An Ontology on Property for Physical, Chemical and Biological Systems" Berzell M., "Electronic Healthcare Ontologies: Philosophy, the real world and IT structures"
Butorphanol is a morphinan-type synthetic agonist–antagonist opioid analgesic developed by Bristol-Myers. Butorphanol is most closely structurally related to levorphanol. Butorphanol is available as the tartrate salt in injectable, tablet, and intranasal spray formulations. The tablet form is only used in dogs, cats and horses due to low bioavailability in humans. It was patented in 1971 and approved for medical use in 1979.
Sources: en.wikipedia.org
This gave SWAPO 41 seats in the territory's Constituent Assembly, but not a two-thirds majority which would have enabled it to unilaterally draft a constitution without the other parties represented. South West Africa formally obtained independence as the Republic of Namibia on 21 March 1990.
nucleobase Sometimes used interchangeably with nitrogenous base or simply base. Any of the five primary or canonical nitrogenous bases – adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U) – that form nucleosides and nucleotides, the latter of which are the fundamental building blocks of nucleic acids. The ability of these bases to form base pairs via hydrogen bonding, as well as their flat, compact three-dimensional profiles, allows them to "stack" one upon another and leads directly to the long-chain structures of DNA and RNA. When writing sequences in shorthand notation, the letter N is often used to represent a nucleotide containing a generic or unidentified nucleobase.
=== Pharmacodynamics === Flupirtine is a selective neuronal KCNQ (Kv7) potassium channel opener. This action is thought to be primarily responsible for its effects. The drug may also act as a GABAA receptor positive allosteric modulator and this action may be involved in its muscle relaxant effects. The drug was long thought to act as an NMDA receptor antagonist, but it does not directly interact with NMDA receptors. Instead, it has been elucidated that flupirtine indirectly inhibits NMDA receptors by opening KCNQ potassium channels. As such, the drug has since been described as an indirect or "functional" NMDA receptor antagonist. Flupirtine was the first KCNQ potassium channel opener to be introduced for medical use.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.